Arkansas is currently home to 731 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Little Rock VA Medical Center, Little Rock, Arkansas
Conditions: Coronary Artery Disease
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Highlands Oncology Group, Springdale, Arkansas
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients
NCT04590833
Recruiting
This proposed study will advance science by providing evidence on the feasibility of a standardized, rigorously designed and delivered exercise program to improve cognition and plasma brain-derived neurotrophic factor (BDNF) levels for individuals with type 2 diabetes. We will also explore how certain genetic variant may influence exercise-induced cognitive improvements and plasma BDNF levels. Findings of the proposed study will establish a comprehensive knowledge base for future research and de... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/07/2022
Locations: University of Arkansas, Fayetteville, Arkansas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
vDOT for Newly Diagnosed Pediatric Asthma
NCT05120323
Recruiting
The goal of this research study is to compare the impact of video directly observed therapy on inhaler technique accuracy with participants receiving video directly observed therapy vs. participants receiving standard asthma care. Participants will be randomized between the two groups. We will follow up and compare the two groups to see if they have improved asthma control as measured by symptom-free days, higher inhaler technique at 3-month follow up, higher checklist scores on a standardized i... Read More
Gender:
All
Ages:
Between 6 years and 11 years
Trial Updated:
12/14/2021
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Asthma in Children
Register for Updates
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
NCT05024695
Recruiting
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
Gender:
All
Ages:
46 years and above
Trial Updated:
08/23/2021
Locations: Vold Vision, Fayetteville, Arkansas
Conditions: Glaucoma
Register for Updates
Community Translation of the Expecting Study
NCT04298125
Recruiting
The Expecting intervention as delivered in prior studies in a clinical setting is described in a previous approved IRB submission (Protocol 202954). The current project will seek to engage community stakeholders to translate Expecting to a community-delivered intervention and to test its acceptability, feasibility, and fidelity in a proof of principle study with 60 expecting mothers.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/30/2021
Locations: Arkansas Children's Nutrition Center, Little Rock, Arkansas
Conditions: Pregnancy Related
Register for Updates
Time Restricted Feeding, Muscle, and Metabolism
NCT04949451
Recruiting
Effective nutrition strategies for combatting and/or preventing obesity still need to be identified. This has been the case despite the numerous and different approaches that have been taken. Potential targets for combatting/preventing obesity have been identified, but long-term solutions have not emerged. This study uses time restricted feeding to study the role of dietary protein in obesity prevention and/or treatment. The objectives are to determine the role of skeletal muscle mass as a drive... Read More
Gender:
All
Ages:
Between 25 years and 50 years
Trial Updated:
06/25/2021
Locations: University of Arkansas, Fayetteville, Arkansas
Conditions: Overweight, Obesity
Register for Updates
Pilot Study on the Effects of Low-Level Laser Therapy Treatment for Acute and Persistent Discomfort
NCT04774783
Recruiting
This study will examine the effectiveness of Low-Level Laser Therapy (LLLT) for the management of pain in various locations of the body. All subjects selected for participation in the study will be assigned to a LLLT treatment group for a duration of 12 sessions.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/24/2021
Locations: Arkansas Colleges of Health Education, Fort Smith, Arkansas
Conditions: Chronic Pain, Acute Pain
Register for Updates
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04718818
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Little Rock, Arkansas
Conditions: Ulcerative Colitis
Register for Updates
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
NCT03942601
Recruiting
This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of femoropopliteal lesions in symptomatic patients with moderate to severe claudication (Rutherford 2-3) or critical limb ischemia (CLI) with rest pain (Rutherford 4). Subjects will be followed for up to 60 months post index procedure.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/31/2020
Locations: Arkansas Heart Hospital, Little Rock, Arkansas
Conditions: Peripheral Arterial Disease
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Pillar Clinical Research, Bentonville, Arkansas
Conditions: Schizophrenia
Register for Updates